查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405841

肢端肥大症治疗市场规模、份额和趋势分析报告：按药物类型、最终用途、地区、细分市场预测，2023-2030 年

Acromegaly Treatment Market Size, Share & Trends Analysis Report By Drug Type (Somatostatin Analogs, GHRA), By End-use (Hospitals & Clinics), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

肢端肥大症治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计2023年至2030年全球肢端肥大症治疗市场规模将以5.7%的复合年增长率增长，2030年达到19.3亿美元。

肢端肥大症盛行率的增加预计将推动成长。例如，根据内分泌学会的报告，2015 年的疾病盛行率比 2014 年增加了四倍。此外，各製药公司增加对临床试验的投资以开发新分子也是推动市场成长的因素。

此外，强大的药品管线预计将在未来几年创造成长机会。例如，Chiasma Inc.的Mycapssa于2016年在欧洲获得核准。 2018年，Antisense Therapeutics在美国推出了新剂型ALT1103。 Ionis Pharmaceuticals Inc.的生长激素受体拮抗ISIS 766720目前正在进行II期临床试验，预计于2019年12月完成。

生长抑制素类似物的强大产品线预计将在不久的将来推动肢端肥大症药物市场的成长。例如，2018年，北美进行了约30项临床试验，其中许多正在等待美国食品药物管理局（FDA）的核准。

肢端肥大症治疗市场报告亮点

  • 由于相同产品的容易可得性和具有成本效益的治疗程序，生长抑制素类似物细分市场预计将在未来几年成为按收益占有率的最大产品细分市场。
  • 医院和诊所的最终用途部分占据了最大的市场占有率，因为所有外科手术都在这些设施中进行。外科医生的便利性预计将进一步推动这一领域的发展。
  • 由于有利的政府保险政策和製药公司不断增加的研发投资，北美在 2022 年占据了主导市场占有率。例如，2018年5月，美国国会核准了《尝试权法案》，该法案允许患者尝试检验的治疗严重疾病的药物，包括肢端肥大症等严重疾病。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章肢端肥大症治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 肢端肥大症治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章肢端肥大症治疗市场：药物类型的估计和趋势分析

  • 肢端肥大症治疗市场：重点
  • 肢端肥大症治疗市场：2022 年和 2030 年药物类型趋势和市场占有率分析
  • 生长抑制素类似物
    • 2018年至2030年市场预测
  • GHRA
    • 2018年至2030年市场预测
  • 其他的
    • 2018年至2030年市场预测

第五章肢端肥大症治疗市场：最终用途估计与趋势分析

  • 肢端肥大症治疗市场：重点
  • 肢端肥大症治疗市场：2022 年和 2030 年最终用途趋势和市场占有率分析
  • 医院和诊所
    • 2018年至2030年市场预测
  • 其他的
    • 2018年至2030年市场预测

第六章肢端肥大症治疗市场：区域估计与趋势分析

  • 区域展望
  • 按地区分類的肢端肥大症治疗市场：市场要点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第七章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Novartis AG
    • Ipsen Pharma
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
    • Chiasma, Inc.
    • Peptron, Inc.
    • WOCKHARDT
    • Dauntless Pharmaceuticals
    • Pfizer Inc.
    • Ionis Pharmaceuticals, Inc.
Product Code: GVR-3-68038-053-8

Acromegaly Treatment Market Growth & Trends:

The global acromegaly treatment market size is expected to reach USD 1.93 billion by 2030, expanding at a CAGR of 5.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of the acromegaly disease is expected to drive the growth. For instance, the disease prevalence increased fourfold in 2015 from its previous year 2014, according to a report by the Endocrine Society. Moreover, growing investment in clinical trials by various pharmaceutical companies to develop new molecules is another factor propelling the market growth.

Furthermore, strong pipeline of drugs is anticipated to create growth opportunities in the forthcoming years. For instance, Mycapssa by Chiasma Inc. received approval in Europe in 2016. In 2018, Antisense Therapeutics launched their new formulation ALT1103 in U.S. ISIS 766720 by Ionis Pharmaceuticals Inc., a growth hormone receptor antagonist is currently under phase II clinical trial and is expected to be finished by December 2019.

The strong pipeline of drugs for somatostatin analogs is expected to propel growth of the acromegaly treatment market in near future. For instance, in 2018 around 30 clinical trials were being conducted in North America and many are waiting for the U.S. Food and Drug Administration (FDA) approval.

Acromegaly Treatment Market Report Highlights:

  • Somatostatin analogs segment is expected to emerge as the largest product segment in terms of revenue share in the forthcoming years, owing to easy availability and cost-effective treatment procedure of the product
  • Hospital and clinics end use segment accounted for the largest market share as all the surgical procedures are performed in these facilities. Easy availability of surgeons Is anticipated to further drive the segment
  • North America held the dominant market share in 2022, due to favorable government insurance policies and increased investment in R&D by the pharmaceutical companies. For instance, In May 2018, U.S. Congress approved the Right to Try bill, wherein patients can try unproven medical therapeutics in case of serious illness including orphan diseases like acromegaly

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Type
    • 1.1.2. End use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Acromegaly Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Acromegaly Treatment Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Acromegaly Treatment Market: Drug Type Estimates & Trend Analysis

  • 4.1. Acromegaly Treatment Market: Key Takeaways
  • 4.2. Acromegaly Treatment Market: Drug Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Somatostatin analogs
    • 4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. GHRA
    • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Acromegaly Treatment Market: End-use Estimates & Trend Analysis

  • 5.1. Acromegaly Treatment Market: Key Takeaways
  • 5.2. Acromegaly Treatment Market: End-use Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals & Clinics
    • 5.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Others
    • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Acromegaly Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Acromegaly Treatment Market by Region: Key Marketplace Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Novartis AG
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Ipsen Pharma
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. SUN PHARMACEUTICAL INDUSTRIES LTD.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Chiasma, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Peptron, Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. WOCKHARDT
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Dauntless Pharmaceuticals
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Pfizer Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Ionis Pharmaceuticals, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 3 North America acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 4 North America acromegaly treatment market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 6 U.S. acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 8 Canada acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Europe acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Europe acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe acromegaly treatment market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 Germany acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 14 UK acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 15 UK acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 16 France acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 France acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Italy acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 19 Italy acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Spain acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 21 Spain acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Sweden acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 Sweden acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Norway acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 25 Norway acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Denmark acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 27 Denmark acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific acromegaly treatment market, by region, 2018 - 2030 (USD Million)
  • Table 31 China acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 China acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Japan acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 Japan acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 35 India acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 36 India acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Australia acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Thailand acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 40 Thailand acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 41 South Korea acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 South Korea acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 44 Latin America acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America acromegaly treatment market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 47 Brazil acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Mexico acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 49 Mexico acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 51 Argentina acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa acromegaly treatment market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 56 South Africa acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 60 UAE acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait acromegaly treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research processes
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Acromegaly treatment: Market outlook
  • Fig. 9 Acromegaly treatment: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Acromegaly treatment market driver impact
  • Fig. 15 Acromegaly treatment market restraint impact
  • Fig. 16 Acromegaly treatment market strategic initiatives analysis
  • Fig. 17 Acromegaly treatment market: Drug type movement analysis
  • Fig. 18 Acromegaly treatment market: Drug type outlook and key takeaways
  • Fig. 19 Somatostatin analogs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 GHRA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Acromegaly treatment market: End use movement analysis
  • Fig. 23 Acromegaly treatment market: End use outlook and key takeaways
  • Fig. 24 Hospital & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Global acromegaly treatment market: Regional movement analysis
  • Fig. 27 Global acromegaly treatment market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)